注射用胸腺素治疗慢性重型肝炎患者的临床研究

目的 观察注射用胸腺素治疗慢性重型肝炎的疗效和不良反应. 方法 回顾性调查198例慢性重型肝炎住院患者, 对照组127例, 给予综合治疗; 治疗组71例, 在综合治疗基础上加用注射用胸腺素1.6 mg , sc, qd, 疗程2周. 比较两组患者的治疗有效率、主要生化指标改善程度、并发症发生率及用药不良反应. 结果 早期及中期患者治疗组有效率高于对照组（P<0.05）, 晚期患者两组有效率差异无显著性（P>0.05）. 治疗组丙氨酸氨基转移酶（ALT）、总胆红素（T-BiL）、凝血酶原活性（PTA）在早期及中期患者改善优于对照组（P<0.01）, 晚期患者两组差异无显著性（P>0.05）. 治疗组患者肝肾综合征及感染的发生率低于对照组（P<0.05或P<0.01）. 无明显用药不良反应. 结论 注射用胸腺素可显著提高慢性重型肝炎早期及中期患者的治疗有效率, 改善肝功能, 减少并发症的发生, 患者耐受性好, 不良反应少. 较早实施治疗可取得较满意的疗效.

Clinical Study of Thymic Peptide for Patients with Chronic Severe Hepatitis

Objective To study the therapeutic effect and adverse reaction of thymic peptide for patients with chronic severe hepatitis. Methods A retrospective study was made on 198 patients in hospital with severe chronic hepatitis.The patients were divided into two groups: the control group for 127 patients with combined therapy and the treatment group containing 71 cases,which were given hypodermic thymic peptide 1.6 mg q.d.for 2 weeks on the basis of combined therapy.The effective rate,amelioration of biochemical factors,incidence of complication,as well as adverse reactions were analyzed between two groups. Results It was more effective for the patients in early-stage and medium-stage of treatment compared with those in control group(P<0.05);while no statistical difference was found between two groups for patients in late-stage of treatment(P>0.05).The incidence of hepatorenal syndrome and infection was lower in treatment group than that in control group(P<0.05 and P<0.01,respectively).The adverse reaction was rare. Conclusion Thymic peptide is able to markedly improve the effective rate of therapy for patients in early-stage and medium-stage of chronic severe hepatitis,ameliorate hepatic function,and reduce the incidence of complication.The patients are well tolerated and the adverse reaction to thymic peptide is rare.The early administration of thymic peptide could obtain satisfactory therapeutic effects.